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Abstract 
Ets-2 repressor factor (Erf) is a relatively little explored member of the Ets (E26 
transformation specific)-domain transcription factor family. It is a phosphoprotein consisting 
of 548 amino acids, with a molecular weight of 75 kDa. Unphosphorylated Erf is a 
transcriptional repressor and induces cell cycle arrest in the G0/G1-phase, thus preventing 
cellular growth and proliferation. To present it is neither known whether endogenous Erf is 
expressed in vascular smooth muscle cells (VSMCs) nor how the phosphorylation of Erf is 
regulated in VSMCs. For this purpose A-10 embryonic rat thoracic aorta VSMC were treated 
with the mitogenic stimuli platelet-derived growth factor (PDGF) or low-density lipoprotein 
(LDL), and phosphorylation of Erf was analyzed by Western blot. Furthermore, to determine 
whether phosphorylation of Erf is dependent on extracellular signal-regulated kinase (Erk)-
1/2, specific Mek-1/2 inhibitors U0126 and PD98059 were used. Additionally, 
phosphorylation of Erk-1/2 and Erf after treatment with the intracellular calcium chelator 
BAPTA/AM, either alone or in combination with PDGF, was investigated. The results show 
that Erf is expressed endogenously in VSMCs and phosphorylated by Erk-1/2 upon mitogenic 
stimulation. Furthermore, a decrease in intracellular calcium concentration, alone or in 
combination with a mitogenic stimulus, leads to increased phosphorylation of Erk-1/2 and 
Erf. These findings suggest that in VSMCs Erf phosphorylation is induced by pro-atherogenic 
agents (PDGF or LDL) via the activation of Erk-1/2 and regulation of Erf phosphorylation 
additionally involves levels of intracellular calcium. Thus, Erf could play an important role in 
VSMC proliferation, dedifferentiation and migration, and contribute towards the development 
of vascular remodelling diseases. 
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Ca2+ Calcium ion with double positive charge 
[Ca2+]i Intracellular calcium concentration 
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1. Introduction 
1.1 Anatomy of an artery 
Arteries can be divided into two different types, elastic and muscular arteries. Elastic arteries, 
including the aorta, have a more central location near the heart and fulfill the function of a 
blood reservoir, maintaining a constant blood flow. Muscular arteries, on the other hand, are 
located in the periphery and control the blood supply to the different organs by varying their 
diameter via nerval influence.1, 2 
The arterial wall is made up of three layers – the tunica intima, tunica media and tunica 
adventitia (Fig. 1).3, 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Anatomy of a human muscular arterial wall. From the innermost to the outermost layer: tunica 
intima with the endothelial layer, lamina elastica interna, tunica media, lamina elastica externa, tunica 
adventitia. (Pictures: Institute of Pathology, Kantonsspital Baden, 2011). 
 
As the innermost layer lining the lumen, the intima forms a barrier between the intravasal and 
the extravasal compartment of the body, preventing the loss of macromolecular substances 
and blood cells yet allowing the exchange of smaller molecules in specialized parts of the 
blood vessels.3-5 The intima is made up of a single layer of endothelial cells as well as the 
Endothelial
layer
Lamina elastica 
interna
Lamina
elastica externa
Media
Adventitia
Intima
© Stephanie Nabholz
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subendothelial space, a loosely-constructed reticular connective tissue containing fibroblasts 
and longitudinally-organized vascular smooth muscle cells (VSMCs).1-4, 6 A band of elastic 
fibers, the lamina elastica interna, separates the intima from the media.1-3, 6 It is less distinct in 
elastic arteries but very prominent in arteries of the muscular type. 4 The media is built up of 
multiple layers of VSMCs and elastic fibers arranged in concentric circles around the lumen 
of the vessel. Finally, the outermost part of the artery is the tunica adventitia, comprising 
elastic and collagen connective tissue, nerves and nerve endings of the vegetative nervous 
system and the vasa vasorum, small blood vessels for the supply of the vessel itself.1-4, 6 The 
adventitia is separated from the media by the lamina elastica externa.1-4 
 
1.2  Vascular smooth muscle cells  
Vascular smooth muscle cells (VSMCs) are highly differentiated smooth muscle cells located 
within the walls of blood vessels, in particular in the media. VSMCs are spindle-shaped, often 
branched cells of approximately 20–300 µm in length with a centrally-located, longish 
nucleus (Fig. 2).1, 3, 7, 8 In elastic arteries such as the aorta, the media contains several 
fenestrated layers of elastic fibers connected by VSMCs embedded in loose connective 
tissue.2, 4 The VSMCs of subsequent layers are arranged in opposite directions to each other, 
thus permitting an adjustment in the thickness of the media depending on the momentary 
blood pressure.4, 9 The media of muscular arteries on the other hand has more layers of 
VSMCs and only a few elastic or reticular fibers.1-4, 10 
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Fig. 2: Histological view of vascular smooth muscle cells in human muscular arteries. a: View of an 
arterial wall with the prominent media and the longitudinally-arranged VSMCs. b: Higher 
magnification of the VSMCs. c: Cross-section of the VSMCs of the tunica media; the nucleus has a 
round shape and is located in the center of the cell. (Pictures: Institute of Pathology, Kantonsspital 
Baden, 2011). 
 
The VSMCs of an elastic arterial wall fulfill two main functions: 1) Regulating the distension 
of the arterial wall during the systolic phase.4, 9 And 2) controlling the elastic recoiling of the 
arterial wall during the diastolic phase. These two mechanical processes help maintain 
constant blood flow in the blood vessels of the body (Windkessel effect).6, 9-11  The VSMCs in 
muscular arteries and arterioles, however, regulate the diameter of the vessels via contraction 
(vasoconstriction) or relaxation (vasodilatation), thereby defining the blood flow per time unit 
in the vessel.3, 10, 11 Looking at the circulatory system as a whole, a cumulative change in the 
total diameter of all the vessels not only affects blood flow but also blood pressure.1, 3, 11 
 
a
b c
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1.2.1 VSMC markers 
The VSMCs in a quiescent, differentiated state have very low rates of proliferation and 
express a specific set of protein markers as described below: 
1. Smooth muscle α-actin  
As a part of the contractile apparatus in differentiated VSMCs, smooth muscle α-actin is 
expressed at high levels. In differentiated VSMCs there are three other isoforms of actin 
(including non-muscle β-actin, non-muscle γ-actin and smooth muscle γ-actin). Smooth 
muscle α-actin accounts for over 40% of the total protein of a VSMC and for over 70% of the 
total actin. During vasculogenesis, the first marker expressed in developing and 
differentiating VSMCs is α-actin. As differentiation continues, the level of expression 
increases. Although smooth muscle α-actin is specific for smooth muscle, it can also be 
expressed in other cells such as myofibroblasts and endothelial cells upon stimulation by 
TGF-β.12 
2. Smooth muscle myosin heavy chains 
Smooth muscle myosin heavy chain (MHC) is another essential component of the contractile 
apparatus of a VSMC. In mature, differentiated VSMCs, there are at least three types of 
smooth muscle MHC, including SM-1 and SM-2, and two types of non-muscle MHCs. SM-1 
and SM-2 are the two most specific markers for the identification of differentiated smooth 
muscle cells, especially SM-2, which is expressed in later stages of differentiation than SM-
1.12 
3. Myosin light chains 
Aside from MHC, myosin contains a pair of non-phosphorylatable myosin light chains 
(MLCs) and a pair of regulatory, phosphorylatable MLCs. In VSMCs there are two non-
phosphorylatable light chain isoforms, namely LC17a and LC17b, whereby higher levels of 
LC17b are associated with reduced ATPase activity in actin-myosin complexes. By 
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comparison, phosphorylatable MLCs exist in a number of isoforms in VSMCs, but also in 
numerous other cell types.12 
4. Calponin and SM-22α 
Calponin is said to have a regulatory function in the contraction of SMCs by interacting with 
F-actin and tropomyosin, as well as calmodulin. It has multiple isoforms, some of them also 
expressed in non-muscle cells. Together with SM-22α, the α- and β-isoforms of calponin are 
specific for adult SMCs. SM-22α is also one of the earliest markers in differentiated SMCs.12 
5. Caldesmon 
Caldesmon (CaD) can be found as two main isoforms in SMCs, h- and l-caldesmon. It binds 
to calmodulin and actin and is therefore thought to play a regulatory role in smooth muscle 
contraction. H-caldesmon is primarily expressed in SMCs and represents a marker for the 
intermediate stage of SMC differentiation, in comparison to l-caldesmon, which is also 
expressed in non-muscle cells.12 
6. Tropomyosin 
Tropomyosin (TM) is expressed in smooth muscle cells as well as in cardiac, skeletal and 
non-muscle cells and binds to the actin filaments of these cells. While it is essentially 
involved in the regulation of contraction in cardiac and skeletal muscle cells, it has a rather 
unclear function in SMCs. A stabilizing effect on actin has been postulated. The isoform α-
TM is specific for SMCs in adult organisms.12 
 
1.2.2 Contractile apparatus of VSMCs 
The contractile apparatus of VSMCs consists of thick myosin filaments and thin actin 
filaments, so-called F-actin. Myosin filaments are polymers of the myosin-II molecule, a 
dimer consisting of two myosin heavy chains (MHC) forming the two heads and tail, and four 
myosin light chains (MLC) including two essential, non-phosphorylatable (ELC) and two 
regulatory, phosphorylatable MLC (RLC).1, 13-15 An assembled myosin filament is 
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approximately 12-18 nm in diameter and contains up to 300 myosin heads.13, 16, 17 F-actin on 
the other hand is a strand-like polymer of individual G-actin monomers with a diameter of 
approximately 5-8 nm.1, 13, 16, 17 The thick filaments are arranged in parallel between the thin 
filaments, with the myosin heads pointing toward the actin filament on either side.1, 8, 13 
Myosin heads have an ATPase activity and the ability to cross link with actin.1, 13, 14, 16, 17 
Associated with the actin filaments are, among other molecules, tropomyosin (TM), 
caldesmon (CaD) und calmodulin (CaM).17 They represent the regulatory apparatus of smooth 
muscle cell contraction. In the unstimulated, relaxed state of the cell, caldesmon is closely 
associated with the actin-TM complex, thereby preventing cross-linking between actin and 
myosin and inhibiting ATPase activity of the myosin heads.1, 13, 17 
The arrival of an external signal followed by the depolarisation of the cell membrane or the 
activation of G-protein coupled receptors (leading to the formation of inositoltriphosphate 
(IP3) via phospholipase C (PLC)) triggers an increase in intracellular calcium concentration, 
both due to influx through transmembrane L-type calcium channels as well as by release from 
the sarcoplasmatic reticulum (SR). The higher intracellular calcium concentration leads to the 
formation of calcium-calmodulin complexes which bind to caldesmon and also activate the 
myosin light chain kinase (MLCK).8, 16, 17 Phosphorylation of the MLC by the MLCK, 
causing conformational change of the myosin heads, as well as exposure of the actin-binding 
site by dislocation of caldesmon enables actin-myosin cross-linking and finally smooth 
muscle cell contraction.1, 8, 13, 16, 17 However, smooth muscle cell contraction is not only 
dependent on a rise in intracellular calcium concentration. It can also be induced by direct 
phosphorylation of calmodulin via the extracellular signal-regulated kinases (Erks), thus 
breaking the bonds between calmodulin and actin. 17  
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1.2.3 Diseases involving VSMCs 
Vascular diseases can affect every layer of the vessel wall and cause functional and structural 
changes particularly in the endothelium and the intima, but also in the VSMCs of the media.3, 
5 By taking a closer look at the development of the most common angiopathy, atherosclerosis, 
the impact of the changes in VSMCs on the architecture of the vessel wall becomes apparent.  
In industrial countries, atherosclerosis and associated complications such as coronary heart 
disease (CHD)/coronary artery disease (CAD) have become the number one cause of death. 
Risk factors involve hypertension, hypercholesterolemia, diabetes mellitus, obesity, male 
gender, metabolic syndrome as well as systemic inflammatory diseases. Moreover, 
environmental factors including nicotine abuse, high-fat diet and lack of adequate exercise 
also contribute to the development of this vascular disease.3, 18 The genesis of an 
atherosclerotic plaque, however, is not dependent on one of these factors only, but is almost 
always multifactorial.3, 18, 19 
The response-to-injury hypothesis 3, 20, 21 in combination with the lipid hypothesis 22 poses a 
possible theory on how atherosclerotic plaques can develop in elastic and muscular arteries.3, 
19 Mechanical stress such as hypertension, as well as inflammation, damage the vessel wall 
and in particular the innermost layer, leading to endothelial dysfunction.3, 20 In the initial stage 
this causes increased endothelial permeability with influx of plasma-derived cholesterol in 
form of lipoproteins such as low-density lipoproteins (LDL) into the intima.3, 18, 20 Reactive 
oxygen species (ROS) and other free radicals such as nitric oxide (NO), produced by the 
surrounding cells of the vessel wall, lead to the oxidation of LDL.3, 18, 23 Oxidized LDL 
(oxLDL) stimulates the expression of cytokines (e.g. tumor necrosis factor, TNFα), 
vasoactive substances (e.g. angiotensin II) and growth factors (e.g. platelet derived growth 
factor, PDGF) in endothelial cells and promotes their release into the intra- and extravasal 
compartment, thereby activating VSMCs in the media.3, 18, 24 LDL and oxLDL, however, can 
also stimulate the VSMCs directly.25 
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By release of chemoattractant molecules and cytokines the endothelial cells are able to attract 
monocytes in the blood and permit them to transmigrate into the vessel wall.3, 18 Stimulated 
by the inflammatory milieu, the monocytes undergo transformation to macrophages that take 
up the oxidized LDL.3, 18, 20, 21, 23 The local inflammatory process eventually turns into a 
chronic systemic inflammatory reaction.3, 18, 21 Once the macrophages are loaded with 
oxidized LDL, they turn into foam cells, initially leading to the formation of subendothelial 
fatty streaks.3, 18-20, 23 With further progression of atherosclerosis, the foam cells die or 
undergo programmed cell death, freeing the phagocytosed lipids and generating a necrotic 
fatty core of the growing atherosclerotic lipid plaque.3, 18, 20 Interestingly, not only 
macrophages undergo this process; VSMCs can also take up oxidized LDL and turn into foam 
cells.18, 19, 23 
Vascular injury in general and atherosclerosis in particular cause VSMCs to migrate to the 
intima where they lose their differentiation markers such as α-actin, smooth muscle MHC, 
caldesmon and desmin.5, 12, 18, 23 26-29 These changes are associated with an increased 
proliferation of VSMCs 3, 5, 18, 26, 29, 30 as well as production of extracellular matrix 
components including collagen, elastin and glycosaminoglycans (GAG),1, 3, 18, 26, 31 ultimately 
causing intimal swelling and vascular remodelling.3, 5, 18, 20, 21, 23, 24, 26, 31 
 
1.3 Cell signaling in VSMC 
Vascular smooth muscle cells express both intracellular/nuclear and cell surface receptors. 
There are three primary forms of cell surface receptors: ion-channel-linked receptors, G-
protein coupled receptors and enzyme-linked receptors including the receptor tyrosine kinases 
(RTKs).13, 32-35 The mechanisms behind transduction of a signal from the extracellular to the 
intracellular space include a conformational change of the receptor, activation of the coupled 
G-protein and dimerization of the receptor followed by autophosphorylation.13, 34-36 For 
example, the simultaneous binding of the dimeric platelet-derived growth factor (PDGF) to 
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two PDGF receptor tyrosine kinases leads to their dimerization and autophosphorylation at 
tyrosine residues.36 One of the most common proteins activated by receptor tyrosine kinases is 
the monomeric GTP-binding protein Ras.13, 37 The extracellular signals transmitted by the 
receptors activate downstream kinases which frequently converge at mitogen-activated 
protein kinases (MAPKs).36, 37 Activation/deactivation of signaling elements takes place 
primarily by the process of phosphorylation or dephosphorylation of amino acids of the target 
molecule at serine, tyrosine and threonine residues.13, 37-39  
 
1.3.1 Role of mitogen-activated protein kinases 
The mitogen-activated protein kinase (MAPK) pathway is one of the most essential signaling 
pathways of many cells, including VSMCs.38-40 Stimulated by mitogens including growth 
factors, hormones and cytokines, it regulates important cell functions such as proliferation, 
gene expression, cell metabolism, differentiation and apoptosis.36-39, 41 The pathway 
constitutes a phosphorelay system of three sequentially phosphorylated and activated protein 
kinases.37-39 The starting point of the entire phosphorylation cascade are the MAPK kinase 
kinases (MKKKs). There are several forms of MKKKs so that the various signals a cell 
receives can be transmitted to the corresponding pathways, thus leading to an adequate 
reaction of the cell to the requirements of its changing environment.38, 39, 41 The MKKKs pass 
on the signal by phosphorylation of the MAPK kinases (MKKs). In the end the 
phosphorylation cascade leads to the activation of the MAPKs, which are serine/threonine-
specific protein kinases.36-39, 42 This relay system allows the cell to amplify the transmitted 
signal and also enables regulatory interventions by other signaling pathways.36, 38 
The best-researched and best-documented MAPKs are the extracellular signal-regulated 
kinases (Erks) and the family of stress-activated protein kinases (SAPKs), including the c-Jun 
N-terminal kinases (Jnks) and the p38s.36, 37, 39  
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Proto-
oncogenes
The Erk-MAPK pathway is put into action by extracellular stimuli, including growth factors 
and cytokines, through activation of the proto-oncogene Ras (Fig. 3).36, 37, 39, 41 Ras is a G-
protein with the ability to pass on a signal to the proto-oncogenes raf A/B/C (c-Raf1, A-Raf 
and B-Raf), the MKKKs of the signaling cascade.36-38, 41 While A-Raf and B-Raf are 
restricted to certain tissues and fulfill more specific functions, Raf-1 is expressed 
ubiquitously.38 Apart from the activation by Ras, Raf is additionally regulated via negative 
feedback inhibition.38 Following arrival of a signal, Raf activates Mek-1 and Mek-2 (the 
MKKs) by phosphorylation at two serine sites.36-38, 41 Finally, Mek-1 and Mek-2 
phosphorylate Erk-1 and Erk-2 (alias p44 and p42 MAPKs, corresponding to their molecular 
weights) at tyrosine and threonine residues.36-38, 41-43 Erk-1/2 represent serine/threonine 
protein kinases with more than 50 substrates 38, 39, 43 involved in increased proliferation and/or 
changes in post-mitotic activity.36-39, 43 
 
Fig. 3: Schematic picture of the Ras-Raf-Mek-Erk signaling pathway. The extracellular signal 
molecule binds to the receptor protein. In the case of the Erk-pathway the G-protein is Ras. The G-
protein passes the signal on to the downstream signaling proteins, which in turn modulate the target 
proteins (e.g. transcription factors). Framed by the red dashed circle are the two proto-oncogenes Ras 
and Raf. (Adapted from: Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK 
pathway by protein interactions. Biochem. J. 2000; 351: 289-305). 
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Erk-2 (p42) has been shown to be phosphorylated during the G1 phase of the cell cycle of 
Chinese hamster ovary cells following a mitogenic stimulus.44 During mid to late G1 phase it 
then shuttles to the nucleus, where it is necessary for cell cycle progression and consequently 
proliferation.44 For this reason, members of the Ras-Raf-Mek-Erk pathway are being 
discussed as potential targets in the treatment of certain types of cancer.37, 45  
In contrast to Erk-1/2, SAPKs (such as Jnks) are activated by inhibition of protein synthesis 
and other stress-triggering events via several different MKKKs.37, 39, 46 The activated Jnks 
phosphorylate and bind the c-Jun protein, an element of the activator protein 1 (AP-1) 
transcription complex that regulates gene transcription (Fig. 4).39, 46  
Further members of the SAPK family are the p38 kinases. The four p38 kinases α, β, γ and δ 
are part of the signaling pathway activated by inflammatory cytokines including interleukins 
and hormones, and stress factors such as osmotic shock and heat shock (Fig. 4).37, 39 
Therefore, p38 kinases play an important role in immune response and the development of 
autoimmune diseases, for example asthma, by regulating the expression of inflammatory 
cytokines.37, 39, 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: MAPK pathways. The first lane shows the pattern of the pathway. The second lane shows the 
Erk-1/2 activation pathway. The third lane shows the Jnk activation pathway. The last lane shows the 
pathway involving activation of p38. (Adapted from: Johnson GL, Lapadat R. Mitogen-Activated 
Protein Kinase Pathways Mediated by Erk, Jnk, and p38 Protein Kinases, Science. 2002; 298: 1911).  
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In VSMCs the activation of the MAPK pathways through mitogens such as platelet derived 
growth factor (PDGF) or low-density lipoproteins (LDL) has been specifically shown to 
induce migration and/or cell proliferation as well as regulation of contractile phenotype.24, 47-57 
Activation of the MAPK pathway and specifically Erk-1/2 can also induce upregulation of 
smooth muscle MHC expression in neonatal rat VSMCs, thus allowing dedifferentiated 
VSMCs to regain contractile function.29 
 
1.3.2 Role of calcium 
Calcium is an important intracellular ion involved in multiple VSMC processes.58, 59 Under 
unstimulated, physiological conditions in muscle cells, intracellular calcium concentration 
[Ca2+]i is tightly regulated and kept at 100 nM.11 It is stored in the so-called sarcoplasmatic 
reticulum as well as in the caveolae along the cell membrane of VSMCs.1, 58, 59 Following 
nerval stimulation by the vegetative nervous system (e.g. via α1-adrenoceptors) as well as 
stimulation by extracellular signals (e.g. LDL, PDGF, angiotensin II and vasopressin), Ca2+ is 
released from the sarcoplasmatic reticulum into the cytoplasm as a result of inositol 
triphosphate (IP3) formation.1, 58-66 In addition there is Ca2+-influx from the extracellular space 
via L-type calcium channels due to depolarization of the cell membrane.1, 13, 58, 59, 65, 67  This 
rise in [Ca2+]i ultimately triggers smooth muscle cell contraction.1, 13, 58, 59, 65 
However, Ca2+ not only plays a role in smooth muscle cell contraction, it is also an important 
mediator and regulator of intracellular signal transduction. Kip et al., showed that reduction of 
[Ca2+]i in VSMCs by the calcium ion antagonist Verapamil or the Ca2+-chelator BAPTA/AM 
induces production of the intracellular second messenger cyclic adenosine monophosphate 
(cAMP) as well as increased Erk-2 signaling and proliferation of VSMCs in adult mice 
thoracic aortas.68 Furthermore, it has been reported that in human aortic VSMCs, reduction of 
[Ca2+]i induces proliferation due to activation of the MAPK pathway.69 
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1.4 Ets-domain transcription factor family 
Transcription factors are proteins with DNA-binding domains. By binding to specific DNA 
regions they regulate the transcription of target genes, thereby affecting cell differentiation, 
proliferation and metabolism.70, 71 
The Ets-domain (E26 transformation-specific sequence of the avian erythroblastosis virus) 
transcription factor family represents a large group of transcription factors expressed partly 
ubiquitously, partly tissue-specifically.26, 71 Members of the family include Ets-1, Ets-2, Erf, 
Fli-1 and the ternary complex factor (TCF)-sub family with Elk-1.71-73 They are involved in a 
multitude of cell functions such as cellular growth, proliferation and differentiation, 
angiogenesis, hematopoiesis, but also in vascular inflammation, remodelling and apoptosis.26, 
70-76 As proto-oncogenes they also play an important role in the development of various solid 
and haematological cancer types.26, 71, 74, 76  
With the exception of Elk-1, SAP-1 and Elf-1, the members of the Ets family share a 
conserved sequence of 85 amino acids.72, 73, 75, 76 The DNA-binding domain of the Ets-domain 
transcription factors constitutes a variation of the winged helix-turn-helix motif and binds to 
gene sequences with a central GGAA/T-motif.26, 70-73, 75, 76 Interactions with specific co-
regulatory proteins can alter DNA-binding properties and increase the specificity of promoter 
recognition. This enables a more precise control of gene expression.70-73, 76 
Along with a multitude of signaling pathways, the Ets-domain transcription factors are 
regulated by the MAPK pathway in particular,71-73, 75-79 including the Erk-1/2 and the SAPK 
pathways (Jnk1 and p38) (Fig. 5).71-73, 76, 77 Phosphorylation of Ets-domain transcription 
factors causes conformational change or a alterations in the subcellular localization, leading to 
enhanced or decreased protein-co-regulator and protein-DNA–binding and, thus, affecting 
transcriptional activity.26, 71, 72, 76 In the case of Ets-2-repressor factor (Erf), phosphorylation 
leads to the export of the protein from the nucleus to the intracellular space and thus to 
limitation of its repressor activity.71, 76, 77 Ets-1, Ets-2 and Erf, as well as Elk-1, are explicit 
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direct targets of the extracellular signal-regulated MAPK pathway (Erk-MAPK pathway).72, 
77-79  
 
Fig. 5: Schematic representation of Ets-domain transcription factor signaling. (Adapted from: 
Sharrocks AD, Brown AL, Ling Y, Yates PR. The ETS-Domain Transcription Factor Family. Int. J. 
Biochem. Cell. Biol. 1997; 29: 1371-1387). 
 
1.4.1 Ets-1 and Ets-2 
1.4.1.1 Function 
Ets-1 and Ets-2 are expressed in a variety of cells, including endothelial cells (Ets-1 and Ets-
2) and VSMCs (Ets-1). 26, 70, 71, 73, 75, 76, 80-90 Interestingly, although Ets-2 is postulated to be 
expressed ubiquitously, its expression in VSMC has not yet been proven. 71  The regulation of 
Ets-1 and Ets-2 is controlled to a great extent by the Erk-MAPK pathway.26, 71-73, 75, 76, 81, 83, 84, 
86, 90 Depending on which amino acid residues are phosphorylated, the activity of Ets-1 
increases or decreases. Phosphorylation of Ets-1 at threonine-38, for example, activates DNA 
binding and target gene transcription, whereas phosphorylation of serine in the Ets-1 
inhibitory domains prohibits DNA binding.26, 87  
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Under physiological conditions Ets-1 and Ets-2 play a critical role in the regulation of 
angiogenesis, apoptosis and the differentiation of myogenic, osteogenic, lymphoid and 
endothelial cell lines.70, 71, 73, 75, 82 Evidence that Ets-2 plays a role in adult angiogenesis has, 
however,  not been provided to date. 75 Furthermore, Ets-1 and Ets-2 play an important role in 
normal embryonic development. Mutations in Ets-1 and Ets-2 in mouse embryos result in 
defective vascular branching and consequently embryonic death around a gestational age of 
E10.5,83 indicating an essential role of Ets-1 and Ets-2 in mouse embryonic development.75, 76, 
83 Homozygous Ets-2 -/- mouse embryos on the other hand did not survive beyond E8.5 as a 
result of inaccurate remodelling of the extracellular matrix and defects in the migration of 
trophoblastic cells.73 Ets-1 and Ets-2 are also essential for the normal development of the 
coronary arteries and the myocardium in chicken embryos. 26, 87 Moreover, they are involved 
in VSMC proliferation in peripheral coronary arteries of chicken embryos.91 
The target genes of Ets-1 and Ets-2 are numerous and mostly affect cell proliferation and 
differentiation, as well as angiogenesis and inflammatory reactions of the cellular 
environment. In VSMCs, Ets-1, for example, regulates transcription of PDGF A-chain and D-
chain,92, 93 PDGF-receptor α,94 vascular endothelial growth factor (VEGF),85 VEGF-
receptor,75 monocytes chemoattractant protein -1 (MCP-1),26, 82 nicotinamide adenine 
dinucleotide phosphate (NAD(P)H) oxidase subunit p47(phox) (leading to increased ROS 
production),95 Sm22α, 26 MMP-1, -2, 26 cyclin-dependent kinase inhibitor p21CIP (causing 
cellular hypertrophy) 82 and Fas ligand (FasL) (regulation of apoptosis).71 In endothelial cells, 
Ets-1 affects the expression of endothelial nitric oxide synthase (eNOS),73 p21CIP (causing cell 
cycle arrest),82 vascular endothelial (VE)-cadherin,70, 71, 73, 75 MMP-1, -3, -9 70 and VEGF-
receptors.71, 73 The common target genes of Ets-2 include MMP-9,73, 83 collagenase1,73 cyclin 
D1,73 VEGF-receptor Flt-1,70, 73, 75 angiopoetin-2 (Ang-2), 75 cdc-2, 71 Bcl-xL 83 and p53.73  
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1.4.1.2 The role of Ets-1 and Ets-2 in disease 
Ets-1 and Ets-2 are involved in the development of various diseases. An increase in 
transcriptional activity of Ets-1 and Ets-2 can induce enhanced cell proliferation, 
inhibition/upregulation of apoptosis, dedifferentiation, inflammatory reactions, vascular 
diseases, tumor-induced vasculogenesis, tumor invasion and even metastasis.26, 50, 71, 76, 80, 82-85, 
88, 90, 94, 95 This is caused either by overexpression at the gene level 71, 76 or by increased 
phosphorylation following stimulation by mitogens and cytokines (angiotensin-II, PDGF, ET-
1, interleukin,26, 82, 95-97 TNFα 26, 82,  86) and reactive oxygen species (ROS).92, 94  
Ets-1, for example, is involved in vascular remodelling after injury and mediation of vascular 
inflammation by promoting dedifferentiation, proliferation and migration of VSMCs 
activation of endothelial cells, extracellular matrix deposition and degradation 26-29, 70, 71, 80, 82, 
84, 85, 88, 89, 94, 98, 99 and recruitment of inflammatory cells such as T-cells and monocytes.26, 80, 82 
These changes are known to occur specifically during development of intimal swelling and 
atherogenesis.3, 18, 19, 26, 40, 41, 50 
Zahn et al., were able to show that in Ets-1-/- mice, expression of monocyte chemoattractant 
protein-1 (MCP-1) and cyclin-dependent kinase inhibitor p21CIP is significantly reduced in the 
presence of angiotensin II compared to the control mice, leading to a decreased recruitment of 
T-cells and macrophages as well as reduced uptake of leucine and thymidine in VSMCs. 
These findings indicate the important role of Ets-1 in mediating vascular inflammation and in 
promoting VSMC growth.82 Angiotensin-II also leads to the Ets-1-dependent generation of 
ROS in VSMCs, thereby sustaining a vascular inflammatory condition.95 Hydrogen peroxide 
(H2O2), on the other hand, functions as a mitogenic stimulus itself, activating Ets-1 and thus 
increasing PDGF-receptor α expression in VSMCs.92, 94 
Kavurma et al., showed that there is a high level of Ets-1 expression in atherosclerotic lesions 
of human carotid arteries.98 Furthermore, an involvement of Ets-1 activation in the 
progression and rupture of cerebral aneurysms due to increased expression of inflammatory 
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cytokines has been observed.80 Overexpression of Ets-1 in VSMCs can also result in 
transcriptional repression of smooth muscle cell markers such as α-actin, MHC and SM22α, 
causing phenotypical switching to a more proliferative and less contractile phenotype.50, 99 and 
inhibit apoptosis of VSMCs. 100 
Enhanced expression of Ets-1 is also found in several human cancer types including breast 
cancer, fibrosarcoma and hepatocellular carcinoma and is associated with a more aggressive 
behaviour of the tumor, including metastasis.71 By regulating gene expression of matrix 
metalloproteinases (MMPs) and VEGF in VSMCs and endothelial cells, Ets-1 may promote 
tumor-induced angiogenesis and tumor invasion, 26, 85, 87-89 such as in hepatocellular 
carcinoma, as mentioned above.71 In situ hybridization experiments showed transcription of c-
Ets-1 in endothelial cells during tumor vascularisation.88 Additionally, expression of Ets-1 in 
human ovarian carcinoma is associated with poor survival.71 
As for Ets-2, its overexpression is found in two of the most common solid human cancer 
types, prostate and breast cancer. Moreover, it is essential for the malignant transformation of 
the lesional cells.76 Ets-2 also has the ability to inhibit apoptosis in macrophages and mouse 
embryonic endothelial cells; this at least partially explains its role in tumorigenesis.71, 72, 76, 83, 
101  
 
1.4.2 Ets-2 repressor factor 
1.4.2.1 Biology of Ets-2 repressor factor 
Ets-2 repressor factor (Erf) was the first member of the Ets-domain transcription factor family 
to be identified as a repressor of gene transcription.73, 76, 77, 102 It is a 75 kDa phosphoprotein 
consisting of 548 amino acids and ubiquitously expressed at a constant level in every type of 
tissue.77, 102, 103 The homology with the other members of the Ets-domain transcription factor 
family is minimal, with the exception of the DNA-binding domain.102, 103  
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Erf is regulated via its subcellular localization.76, 77, 103 In the unphosphorylated state, Erf 
binds to the promoter region of the ets-2 gene inside the nucleus, preventing its transcription. 
Upon activation of the Ras/Erk-1/2-MAPK pathway, Erf is phosphorylated and exported to 
the cytoplasm, exposing the DNA-promoter region of ets-2 which can now be transcribed, 
causing increased cell proliferation .71, 73, 75-77, 102-104 Experiments with the Mek-1 inhibitor 
PD98059 were able to identify Erk-1/2 as the predominant regulator of Erf.103  
However, Erf does not only mediate its anti-proliferative and growth-impeding effect via 
inhibition of ets-2 transcription; it also interacts with further growth and proliferation-
stimulating genes such as c-myc and possibly c-fos by binding to their promoter regions.77, 102-
104 C-myc is a transcription factor with the ability to promote VSMC proliferation following 
activation by Erk-1/2.37, 105 Regulation of c-myc transcription by DNA binding to the 
promoter region is dependent on multiple co-factors associated with Erf, such as E2F2, E2F4, 
E2F5 and the retinoblastoma protein(pRb) family.104 
 
1.4.2.2 Nuclear shuttling of Erf 
Extensive multisite phosphorylation by nuclear Erk-1/2 leads to the active export of Erf out of 
the nucleus.76, 103 Export shuttling is dependent on chromosome region maintenance-1 (CRM-
1).77 Interestingly, the import of Erf into the nucleus can occur in both phosphorylated and 
unphosphorylated states, indicating that phosphorylated Erf can be shuttled bidirectionally.77 
Nevertheless, phosphorylated Erf is predominantly located in the cytoplasm and 
dephosphorylated Erf in the nucleus, as shown in rat embryonic fibroblasts.77  
The change in subcellular localization of Erf occurs rapidly following adequate stimuli. Le 
Gallic et al., were able to demonstrate that 10 to 15 minutes after mitogenic stimulation, Erf 
was completely phosphorylated and relocated to the cytoplasm. However, following serum 
deprivation, all Erf was transported back to the nucleus within 30 to 45 minutes.103 
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1.4.2.3 Function of Erf 
Erf is a transcriptional repressor and regulator of cellular proliferation and growth.103 
Embryonic death at 10.5 days post coitum in Erf -/- mice is suggestive of an essential role of 
Erf in mouse embryonic development and survival.106 Experiments with phosphorylation-
defective mutant Erf mouse embryonic fibroblasts were able to show that Erf induces cell 
cycle arrest by blocking progression of the cell cycle through G1 phase and arresting it in 
G0/G1 phase.77, 102, 103 Moreover, it leads to suppression of Ras-induced tumorigenity.103 A 
decrease in the repressing activity of Erf thus causes a higher risk of tumorigenesis.72, 102, 103 
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1.5 Aim of the study 
Until now it is not known whether Erf protein expression occurs in VSMCs and how its 
phosphorylation is regulated. 
 
Therefore we posed the following questions: 
Is Ets-2 repressor factor expressed and/or phosphorylated in VSMCs? 
Is Erk-1/2 an upstream regulator of Erf-phosphorylation? 
Does Ca2+ regulate Erf-phosphorylation? 
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2. Materials and Methods 
2.1 Materials, Chemicals and Antibodies 
Complete growth medium used for cell cultures was high glucose Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% FCS, 1% L-glutamine and 1% penicillin-
streptomycin (PS). DMEM was purchased from Invitrogen Life Sciences (Switzerland). FCS, 
glutamine, PS and DMSO were obtained from Sigma-Aldrich (Switzerland).  
The mitogen PDGF was obtained from Peprotech (UK) and the inhibitors BAPTA/AM, 
PD98059 and U0126 from Enzo Life Sciences (Switzerland). LDL was prepared in the 
laboratory. 
The Bradford protein assay kit was obtained from Bio Rad Laboratories GMBH 
(Switzerland). The 8-10% SDS-PAGE gels were purchased from Invitrogen (Switzerland). 
Hybond ECL Nitrocellulose membranes, enhanced chemiluminescence (ECL) reagent and 
HyperfilmTM ECL were obtained from GE-Healthcare Life Sciences (Switzerland).  
Goat anti-Erf and rabbit anti-total-Erk-1/2 antibodies were purchased from Santa Cruz 
Biotechnology Inc. (U.S.A.) Rabbit anti-phospho-Erk-1/2 antibody was obtained from Cell 
Signaling Technology (U.S.A.) and mouse anti-tubulin antibody from Sigma-Aldrich 
(Switzerland). All remaining reagents were purchased from Sigma-Aldrich (Switzerland).  
 
2.2  Cell line and cultures 
The cell line used for the experiments was the A-10 rat embryonic thoracic aorta vascular 
smooth muscle cell obtained from American Type Culture Collection (ATCC) USA. Cells 
were stored in cryoprotectant medium containing 5% DMSO in liquid nitrogen.  
For use in the experiments, frozen vials of A-10 cells were carefully thawed in a water bath at 
37°C and added to 4 ml warmed complete medium. Then the cells were centrifuged for 5 
minutes at 1000 rpm and the supernatant was discarded. The remaining pellet was re-
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suspended in 10 ml complete medium. 1 ml containing 1x105 cells/ml was plated onto a        
10 cm culture dish and 9 ml of complete medium added. The cells were then incubated at 
37°C with 5% CO2. Every three days the medium was changed and the cells checked under 
the microscope. At a confluence of 80% to 90%, the cells were either sub-cultured further or 
frozen in freezing medium (95% complete medium and 5% DMSO).  
For sub-culturing the complete medium was removed and the cells were washed with 4 ml 
phosphate buffer saline (PBS) followed by addition of 1 ml trypsin. The cells were 
maintained at a temperature of 37°C for 10 minutes until detachment. Detachment was 
verified under the microscope and 4 ml of complete medium added. The cells were 
centrifuged again for 3 minutes at 1000 rpm. The supernatant was removed and fresh medium 
added. After careful suspension, 50’000 cells/ml were pipeted into each well of a 6-well plate 
for subsequent experiments.  
 
2.3 Stimulation of A-10 cells 
For the experiments, the cells were allowed to grow to approximately 80% -90% confluence 
in a 6-well plate. 24 hours prior to the experiment the cells were washed with 2 ml PBS and 
rendered quiescent by starvation overnight in 2 ml of starving medium (DMEM medium 
without FCS). On the day of the experiment, 30 minutes prior to starting, the 2 ml starving 
medium was removed from each well and replaced with 1 ml of fresh starving medium. The 
cells were left undisturbed in the incubator for 30 minutes at 37°C.  
In order to analyze the effect of pro-mitogenic stimuli on the phosphorylation of Erf, the A-10 
vascular smooth muscle cells were treated with PDGF or LDL. These mitogens are known 
activators of the MAPK pathway, as experimentally demonstrated by various other groups in 
the past.24, 47-51, 107, 108 
The cells were pre-treated either with U0126 (10 µM) or PD98059 (25 µM) for 30 minutes or 
45 minutes, respectively, at 37°C. 51, 107, 109-114 Control cells were treated with 0.1% DMSO 
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which was used to dilute the inhibitors U0126 and PD98059, for the same period of time. 
Then the cells were either stimulated with PDGF (10 ng/ml) or with LDL (50 ng/ml) for an 
additional 10 minutes at 37°C.107, 108, 115, 116 After the incubation period, the medium was 
removed from the wells and 80 µl RIPA lysis buffer (Tris(hydroxymethyl)amino methane 
(Tris-HCl): 50 mM, pH 7.4; NaCl: 150 mM; ethylenediaminetetraacetic acid (EDTA): 1 mM; 
sodium deoxycholate: 0.25%; surfactant detergent NP-40: 1%; protease inhibitor cocktail 
(Complete mini Tablet, Roche, Switzerland); sodium orthovanadate (Na3VO4);  
phenylmethylsulfonyl fluoride (PMSF)) was added for 20 minutes to lyse the cells on ice. The 
lysates were then scraped from the wells, collected in eppendorf tubes and frozen in liquid 
nitrogen. Until further processing the samples were stored in the freezer at -25°C. 
Mek-1/2-inhibitor PD98059 [2-(2'-amino-3'-methoxyphenyl)-oxanaphthalen-4-one],  
discovered by Dudley et al., is a selective inhibitor of the MAPK/Erk kinases 1 and 2 (Mek-
1/2) with no significant influence on the MAPKs itself.107, 112 As reported by Dudley et al. and 
confirmed by Favata et al., the IC50 for PD98059 is ~ 10 µM.107, 109 
On the other hand, as Favata et al. showed, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-
aminophenylthio] butadiene) is a highly-selective Mek-1/2 inhibitor with a 100-fold  higher 
affinity for Mek-1/2 than PD98059. A concentration of 10 µM U0126 is sufficient for the 
100% inhibition of Erk-1/2 phosphorylation. Half-maximal activity is reached at 1 µM 
U0126;109 the IC50 of U0126 is 0.07 µM. Both inhibitors of the MAPK pathway are non-
competitive inhibitors, probably of common or overlapping binding sites.109  
To investigate the effect of intracellular calcium concentration in VSMCs, the calcium 
chelator BAPTA/AM was added.24, 51, 68, 111 The cells were pre-incubated with BAPTA/AM 
(10 µM) for 45 minutes and the control cells were treated for the same period of time with 
0.1% DMSO, which was used to dilute the inhibitor BAPTA/AM . During that time the plates 
were incubated at 37°C. Afterwards, the cells were stimulated with PDGF (10 ng/ml) for 10 
minutes at 37°C and the subsequent steps were performed as described above.107, 108 
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BAPTA/AM is a potent intracellular Ca2+ chelator.24, 68, 111 Previously, 20 µmol/l of 
BAPT/AM has been reported to be used in VSMCs.68 
 
2.4  Protein estimation 
The protein concentration was determined with the aid of the Bradford Protein Assay kit from 
Bio-Rad in accordance with the manufacturer’s instructions.117 Bovine serum albumin (BSA, 
1 mg/ml) was used to make the protein standard series with concentrations of 500, 250, 125, 
62.5, 31.25, 15.625, and 7.8125 (in µg/ml). Diluted lysis buffer was used as a control. The 
lysates were thawed and centrifuged at 13,200 rpm for 10 minutes at 4°C to separate the cell 
detritus from the proteins in the supernatant, which was transferred to fresh eppendorf tubes. 
The samples (lysates) were diluted 10 times with water. Then 10 µl of the standards and 10 µl 
of the diluted samples were pipeted in duplicate into a 96-well plate. 200 µl of Bradford 
solution was added to each well and the plate was incubated for 5 minutes at room 
temperature. Protein concentration was determined using a photospectrometer (Bucher Biotec 
AG, Switzerland) at 595 nm. The sample concentrations were determined using the standard 
curve.  
 
2.5  Western blotting 
2.5.1 Protein separation 
The proteins were separated by SDS-PAGE using 8-10% acrylamide gels. Before loading, the 
proteins were denatured by heating at 95°C for 5 minutes and centrifuged for 1 minute. Equal 
concentrations of protein were then loaded into each lane; the maximum volume was 20 µl. 
Protein marker mix containing proteins with defined molecular weights were also loaded on a 
separate lane. The gel was inserted in a chamber which was filled with running buffer (Tris-
buffer: 25 mM, pH 10.5; glycine: 192 mM; SDS: 0.1%) and was exposed to a current of 80 V 
of direct current for 15 – 20 minutes followed by a current of 130 V for a total of 2 hours.  
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2.5.2 Protein transfer 
The proteins separated by electric current were then transferred to a nitrocellulose membrane 
in transfer buffer (SDS-PAGE running buffer + 20% methanol) at 110 mA per membrane for 
a maximum of 2 hours. After the transfer, the membranes were checked for proteins with 
Ponceau S stain. The molecular weight of Erf is 75 kDa,102 tubulin 55 kDa 118 and Erk-1 (p44) 
and Erk-2 (p42) 44 kDa and 42 kDa, respectively.43, 119 
 
2.5.3 Antibody-staining 
The membranes were washed and blocked for 1 hour with NET-gelatine buffer (NaCl:      
0.15 M; EDTA: 5 mM, pH 8.0; Tris: 0.1 M, pH 7.5; Triton X-100: 0.05%; 2.5 g gelatine in 1 
liter of water; final pH: 7.5), which was replaced every 15 minutes. Following initial blocking 
with NET-gelatine, the membranes were incubated overnight with the primary antibodies 
(anti-Erf or phospho-Erk-1/2) at 4°C, rocking gently. After washing again for 1 hour with 
NET-gelatine buffer to eliminate unbound antibodies, the membranes were incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-goat, anti-rabbit, and 
anti-mouse as required) for 1 hour, rocking gently at room temperature. The membranes were 
then repeatedly washed with NET-gelatine buffer for one hour at room temperature. 
The protein detection and semi-quantitative analysis was carried out with the help of 
enhanced chemiluminescence (ECL).24, 103, 111, 120 The membranes were incubated in 4 ml of 
the ECL reagents (2 ml of reagent A and 2 ml of reagent B) for 1 minute. The horseradish 
peroxidase (HRP) on the secondary antibodies oxidizes the luminol in the ECL reagents, 
leading to the emission of light that can be captured on film.120 After washing with ECL, the 
blots were then placed in light-protected film cassettes together with the films (Amesham 
HyperfilmTM ECL, GE Healthcare, UK). The exposure time varied from 30 seconds to 30 
minutes to achieve a uniform strong signal on the film.  
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To detect if equal amounts of protein were loaded, the membranes were cleared of antibodies 
by stripping with 0.2 M NaOH for 15 minutes, followed by repeated washing for 2 hours in 
NET-gelatine buffer. Membranes were reblotted either with tubulin 121 or with total-Erk.51  
 
2.6  Densitometry and statistical analysis 
The developed blots were scanned (Epson Twain) and processed with Adobe Photoshop. 
Using the program NIH Image J, the density of the protein on the blots was measured 
individually for each lane and inserted into a Microsoft Excel file. The background was also 
measured for each lane and subtracted. Each set of experiments was performed 3 times and 
the mean values were calculated. The statistical analysis was carried out with the program 
StatView using the unpaired Students’t-Test. Data are given as means ± standard error of the 
means (S.E.M.). A P value < 0.05 was considered statistically significant. The unstimulated 
cells were taken as the 100% mark and used as the reference. 
 
 - 33 - 
3. Results 
3.1 PDGF-induced Erf phosphorylation is mediated by Erk-1/2 
 A-10 VSMCs treated with PDGF showed a 1.6-fold increase in Erf phosphorylation 
compared to unstimulated cells (Fig. 6; Unstimulated: 100% vs. PDGF: 159.9 ± 15.7%; 
P<0.05). In unstimulated cells, treatment with U0126 led to a reduction in basal Erf 
phosphorylation of 50% compared to the cells treated with 0.1% DMSO (0.1% DMSO: 100% 
vs. U0126: 53.9 ± 7.1%; P<0.05). Additionally, in cells treated with U0126 and PDGF, Erf 
phosphorylation was reduced by 3-fold in comparison with cells treated with PDGF only 
(PDGF:  159.9 ± 15.7% vs. U0126 + PDGF: 52.1 ± 11.2%; P<0.05). The level of Erf 
phosphorylation was similar in cells treated with U0126 in the absence or presence of PDGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Erf phosphorylation in VSMC. Cells were treated in the absence or presence of U0126          
(10 µM) followed by treatment with PDGF (10 ng/ml). Unstimulated cells were treated either with 
0.1% DMSO or U0126 (10 µM). Values represent percentage of Erf phosphorylation and are means ± 
standard error (n=3). *P < 0.05 vs. unstimulated, † P < 0.05 vs. PDGF. Values were compared using 
the unpaired t-test. The corresponding Western blots show the levels of phosphorylated Erf and total 
Erf. Protein loading was examined with tubulin. The dashed line on the Erf blot represents the cut-off 
used for differentiating between phosphorylated and unphosphorylated Erf. 
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In order to confirm that U0126 was indeed functional, we checked for the phosphorylation of 
Erk-1/2. The treatment of vascular smooth muscle cells (A-10) with PDGF led to a 4.4-fold 
increase in Erk-1/2 phosphorylation compared to unstimulated cells (Fig. 7; Unstimulated: 
100% vs. PDGF: 439.0 ± 45.5%; P<0.05). The treatment of unstimulated cells with U0126 
decreased the basal phosphorylation of Erk-1/2 by 6.6-fold compared to cells treated with 
0.1% DMSO (0.1% DMSO: 100% vs. U0126: 15.6 ± 4.1%; P<0.05). There was a reduction 
in Erk-1/2 phosphorylation by 24-fold in the cells treated with U0126 and PDGF compared to 
cells treated with PDGF only (PDGF: 439.0 ± 45.5% vs. U0126 + PDGF: 18.4 ± 2.7%; 
P<0.05). The level of Erk-1/2 phosphorylation was similar in cells treated with U0126 in the 
absence or presence of PDGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Erk-1/2 phosphorylation in VSMC. Cells were treated in the absence or presence of U0126   
(10 µM) followed by treatment with PDGF (10 ng/ml). Unstimulated cells were treated either with 
0.1% DMSO or U0126 (10 µM). Values represent percentage of Erk-1/2 phosphorylation and are 
means ± standard error (n=3). *P < 0.05 vs. unstimulated, † P < 0.05 vs. PDGF. Values were 
compared using the unpaired t-test. The corresponding Western blots show the levels of 
phosphorylated Erk-1/2 and total Erk-1/2. 
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3.2  LDL-induced Erf phosphorylation involves Erk-1/2 activation 
The stimulation of A-10 VSMCs with LDL led to a 1.4-fold increase in Erf phosphorylation 
in comparison to unstimulated cells (Fig. 8; Unstimulated: 100% vs. LDL: 137.5 ± 3.0%; 
P<0.05). Treatment of the cells with PD98059, followed by LDL, reduced Erf 
phosphorylation by a factor of 1.2 compared to treatment with LDL only (LDL: 137.5 ± 3.0% 
vs. PD98059 + LDL: 112.3 ± 4.9%; P<0.05). Compared to the cells treated with 0.1% 
DMSO, treatment with PD98059 led to a 1.3 fold reduction in basal Erf phosphorylation 
(0.1% DMSO: 100% vs. PD98059: 74.5 ± 4.4%; P<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Erf phosphorylation in VSMC. Cells were treated in the absence or presence of PD98059     
(25 µM) followed by treatment with LDL (50 µg/ml). Unstimulated cells were treated either with 
0.1% DMSO or PD98059 (25 µM). Values represent percentage of Erf phosphorylation and are means 
± standard error (n=3). *P < 0.05 vs. unstimulated, † P < 0.05 vs. LDL. Values were compared using 
the unpaired t-test. The corresponding Western blots show the levels of phosphorylated Erf and total 
Erf. Protein loading was examined with tubulin. The dashed line on the Erf blot represents the cut-off 
used for differentiating between phosphorylated and unphosphorylated Erf. 
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To confirm that PD98059 was functional, it was necessary to check the status of Erk-1/2 
phosphorylation. The application of PD98059 to the vascular smooth muscle cells led to a 3-
fold reduction in basal Erk-1/2 phosphorylation compared to cells treated with 0.1% DMSO 
(Fig. 9; 0.1% DMSO: 100% vs. PD98059: 33.2 ± 8.7%; P<0.05). Stimulation with LDL 
caused a 1.8-fold increase in Erk-1/2 phosphorylation in comparison with unstimulated cells 
(Unstimulated: 100% vs. LDL: 179.4 ± 1.4%; P<0.05). Treatment of the cells with PD98059 
and LDL caused Erk-1/2 phosphorylation to drop by a factor of 1.6 compared to the cells 
stimulated with LDL only (LDL: 179.4 ± 1.4% vs. PD98059 + LDL: 110.9 ± 14.7%; P<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: Erk-1/2 phosphorylation in VSMC. Cells were treated in the absence or presence of PD98059 
(25 µM) followed by treatment with LDL (50 µg/ml). Unstimulated cells were treated either with 
0.1% DMSO or PD98059 (25 µM). Values represent percentage of Erk-1/2 phosphorylation and are 
means ± standard error (n=3). *P < 0.05 vs. unstimulated, † P < 0.05 vs. LDL. Values were compared 
using the unpaired t-test. The corresponding Western blots show the levels of phosphorylated Erk-1/2 
and total Erk-1/2.  
 
Phosphorylated Erk1/2
0
20
40
60
80
100
120
140
160
180
200
%
 E
rk
-1
/2
 p
ho
sp
oh
ry
la
tio
n
Phosphorylated Erk-1/2
Total Erk-1/2
Un
sti
mu
lat
ed
 
(0.
1%
 D
MS
O)
PD
98
05
9
PD
98
05
9 +
 LD
L
LD
L
*
†
*
-1/2
 - 37 - 
3.3  Erf and Erk-1/2 phosphorylation are mediated by depletion of 
intracellular Ca2+  
Vascular smooth muscle cells (A-10) stimulated with PDGF showed a 2.8-fold increase in 
phosphorylated Erf compared to unstimulated cells (Fig. 10; Unstimulated: 100% vs. PDGF: 
277.9 ± 31%; P<0.05). Treatment of the cells with BAPTA/AM only increased Erf 
phosphorylation by a factor of 2.6 compared to the cells treated with 0.1% DMSO (0.1% 
DMSO: 100% vs. BAPTA/AM: 263.3 ± 22.4%; P<0.05). Treatment of the cells with both 
PDGF and BAPTA/AM resulted in a noticeable rise in Erf phosphorylation in comparison 
with the cells stimulated with PDGF only; the values, however, were not significant (PDGF: 
277.9 ± 31% vs. PDGF + BAPTA/AM: 324 ± 12.4%; P=0.24). It was interesting to note that 
the level of Erf phosphorylation was similar in cells treated with PDGF or with BAPTA/AM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: Erf phosphorylation in VSMC following intracellular calcium depletion. Cells were treated in 
the absence or presence of BAPTA/AM (10 µM) followed by treatment with PDGF (10 ng/ml). 
Unstimulated cells were treated either with 0.1% DMSO or BAPTA/AM (10 µM). Values represent 
percentage of Erf phosphorylation and are means ± standard error (n=3). *P < 0.05 vs. unstimulated. 
Values were compared using the unpaired t-test. The corresponding Western blots show the levels of 
phosphorylated Erf and total Erf. Protein loading was examined with tubulin. The dashed line on the 
Erf blot represents the cut-off used for differentiating between phosphorylated and unphosphorylated 
Erf. 
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Whether calcium plays a regulatory role in mediating the phosphorylation of Erk-1/2 was also 
examined. The addition of PDGF to vascular smooth muscle cells (A-10) caused a 4.7-fold 
increase in Erk-1/2 phosphorylation compared to unstimulated cells (Fig. 11; Unstimulated: 
100% vs. PDGF: 468.3 ± 19.6%; P<0.05). The treatment of unstimulated cells with 
BAPTA/AM also caused a 2.7-fold increase in Erk-1/2 phosphorylation compared to the cells 
treated with 0.1% DMSO (0.1% DMSO: 100% vs. BAPTA/AM: 268.3 ± 69.9%; P<0.05). 
Interestingly, stimulation of cells with both BAPTA/AM and PDGF potentiated Erk-1/2 
phosphorylation by a factor of 4.1 compared to cells solely treated with PDGF (PDGF: 468.3 
± 19.6%, PDGF + BAPTA/AM: 1932.8 ± 69.9%; P<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: Erk-1/2 phosphorylation in VSMC. Cells were treated in the absence or presence of 
BAPTA/AM (10 µM) followed by treatment with PDGF (10 ng/ml). Unstimulated cells were treated 
either with 0.1% DMSO or BAPTA/AM (10 µM). Values represent percentage of Erk-1/2 
phosphorylation and are means ± standard error (n=3). *P < 0.05 vs. unstimulated, † P < 0.05 vs. 
PDGF. Values were compared using the unpaired t-test. The corresponding Western blots show the 
levels of phosphorylated Erk-1/2 and total Erk-1/2. 
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4. Discussion 
4.1  Summary 
In the present study the expression of endogenous Erf and its phosphorylation is shown to 
occur in VSMCs and the regulation of Erf phosphorylation is mediated by Erk-1/2 following 
mitogenic stimulation. Additionally, a decrease in intracellular calcium concentration, using 
an intracellular calcium chelator, acts as a mitogenic stimulus and increases phosphorylation 
of Erk-1/2 and Erf (Fig. 12).  
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Schematic diagram showing regulation of Erf phosphorylation by mitogens and [Ca2+]i. 
Mitogens (PDGF or LDL) bind to their cognate receptor. In this model, the PDGF receptor transfers 
the signal to the intracellular space by activating Ras, Raf and Mek-1/2. This signal further activates 
Erk-1/2, which in turn phosphorylates Erf. Additionally, BAPTA/AM reduces [Ca2+]i by chelation of 
calcium, leading to induction of Erk-1/2 and Erf phosphorylation.  
 
The experimental findings suggest that pro-atherogenic mitogens (such as PDGF or LDL) and 
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leading to VSMC proliferation, dedifferentiation and migration. Thus, phosphorylation of Erf 
may contribute to the pathogenesis of vascular diseases and its consequences.  
 
4.2 Expression of Erf in VSMCs 
The experiments on which the present study is based provide evidence for the expression of 
endogenous Erf in rat embryonic thoracic aorta VSMCs. This is the first study showing 
expression of endogenous Erf in VSMCs. Since VSMCs represent an important, integral 
element of the vasculature this as an important finding. However, it is still not known whether 
Erf is expressed in endothelial cells. 
Under normal conditions, VSMCs are quiescent. However, during atherogenesis, driven by 
mitogenic stimuli, VSMCs migrate from the media to the intima, where they begin to 
proliferate, dedifferentiate and synthesize extracellular matrix components, causing intimal 
swelling and eventually atherosclerosis.3, 18, 24, 26-28, 30, 31  
The Ets-2 repressor factor (Erf) belongs to a large family of transcription factors, the Ets-
domain transcription factor family.77 Consisting of numerous members, including Ets-1, Ets-
2, Fli-1 and Elk-1, this transcription factor family regulates the expression of multiple target 
genes, mostly as a transcription activator.26, 70-73, 75, 77, 102, 103 Erf however is an unique member 
of the family, since it acts as a transcription repressor.77, 102, 103  
Previous studies on Erf have generally focused on cancer cells such as lung cancer cells, 
osteosarcoma cells (Saos-2), cervical cancer cells (HeLa), human teratocarcinoma cells (T2), 
human Ewing's sarcoma cells and v-Abelson leukemia virus transformed mouse leukemic 
monocytic cells.77, 102, 103, 122-124 The expression of Erf has also been studied in mouse and rat 
embryonic fibroblasts, mouse myoblasts, liver tumor-infiltrating (TILs) CD8 T lymphocytes 
and even Drosophila S2 embryonic cells.77, 103, 104, 125, 126  
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The present finding, that Erf is also endogenously expressed in VSMCs, is interesting and 
may suggest its role in atherogenesis and the development of other angiopathies. 
 
4.3 Phosphorylation of Erf is mediated by Erk-1/2 in VSMCs 
Vascular smooth muscle cells are highly differentiated components of the vessel wall and 
found predominantly in the tunica media.1, 2, 10 Here they contribute towards maintaining a 
constant blood flow in the large vessels of the body (Windkessel effect) and regulate organ 
perfusion and blood pressure.2, 4, 6, 9-11 In the quiescent state, VSMCs proliferate at a very low 
rate and express specific markers such as smooth muscle α-actin, smooth muscle myosin 
heavy chains, myosin light chains, SM-22α, calponin, caldesmon and tropomyosin.12 
Upon mitogenic stimuli with PDGF, LDL, angiotensin II or with reactive oxygen species 
(ROS) VSMCs start to proliferate and migrate to the intimal layer.24, 48, 51, 52, 56, 57, 127-134 
Chemotactic relocation is accompanied by a switch of the VSMCs from a quiescent 
phenotype to a proliferative, invasive phenotype, including gradual dedifferentiation, 
resistance to apoptosis and the loss of the specific contractile markers, especially smooth 
muscle α-actin, smooth muscle MHC, SM-22α, vinculin, caldesmon and desmin. 12, 18, 26-29, 50, 
130, 135-139 The proliferative, dedifferentiated phenotype is furthermore characterized by an 
increased expression of matrix metalloproteinases and the phenotypic markers tropomyosin 4 
(TM4) and myosin heavy chain embryonic (SMemb), as well as by the beginning of 
extracellular matrix (ECM) synthesis (glycosaminoglycan, collagen and elastin).3, 18, 26, 130, 137, 
140-142 Phenotypic switch of VSMCs, along with other processes, finally contributes to 
neointimal hyperplasia, the basis for vascular remodeling diseases (VRD) such as 
atherosclerosis or restenosis.3, 12, 18, 26, 31, 50, 52, 54, 135, 142  
The predominant molecular pathway leading to the induction of the phenotypic switch in 
VSMCs is the mitogen activated protein kinase (MAPK) pathway.26, 143, 144. It regulates 
essential functions and processes of the cell such as proliferation, differentiation, apoptosis 
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and gene expression.36-41 Present already in unicellular organisms, the members of the 
MAPKs are highly conserved serine/threonine kinases.145 The best known and most important 
exponents of the MAPKs are the extracellular-signal-regulated kinases-1/2 (Erk-1/2), the Jnks 
and p38.39  
In the present study, the experimental results suggest that in VSMCs, phosphorylation of Erf 
is controlled by Erk-1/2, as inhibition of Erk-1/2 by specific chemical Mek-1/2 inhibitors 
(U0126 or PD98059) reduced Erf phosphorylation significantly. The validity of Mek-1/2 
inhibition was tested by checking the levels of Erk-1/2 phosphorylation. In cells treated with 
U0126, phosphorylation of Erk-1/2 was completely blocked, whereas Erf phosphorylation 
was decreased significantly, yet not abolished, suggesting that activated Erk-1/2 is not the 
only upstream mediator of Erf phosphorylation. Similar results were also obtained in the 
presence of PD98059, wherein the extent of inhibition of Erk-1/2 phosphorylation did not 
correlate completely with Erf phosphorylation. Again this is suggestive of the fact that other 
upstream effector molecules contribute to Erf phosphorylation besides Erk-1/2. The inhibitory 
influence of the Mek-1/2 inhibitor PD98059 was not as strong as U0126, especially after 
treatment with a mitogenic stimulus, confirming the lower affinity of PD98059 to Mek-1/2 
than U0126. Similar data has been presented by Favata et al.109 
In the present experiments VSMCs were stimulated with PDGF and LDL for a period of 10 
minutes, leading to Erk-1/2 and Erf phosphorylation. This short stimulation of VSMCs can 
lead to cell migration.40 Time-dependent stimulation experiments by Nelson et al., showed 
that mitogen induced MAPK activity of up to 15 minutes is necessary for cellular chemotaxis, 
whereas a MAPK activity of at least 1 and at the most 4 hours is required for VSMC 
proliferation.40 
In its unphosphorylated state Erf is able to induce cell cycle arrest in the G0/G1-phase by 
blocking progression of the cell cycle through G1 phase,77, 102, 103 therefore acting as an 
essential regulator of cellular proliferation and growth.77, 102, 103 Sgouras et al., showed that in 
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mouse embryonic fibroblasts, phosphorylation of Erf is regulated via mitogenic stimulation 
and activation of the Ras/MAPK pathway and that phosphorylation of Erf inhibited its 
repressor activity.102 Le Gallic el al., even identified Erk-1/2 as the predominant regulator of 
Erf in rat embryonic fibroblasts.103 However, stress-activated protein kinases (p38 and Jnks) 
are not reported to induce phosphorylation of Erf.103 Following phosphorylation by Erk-1/2 in 
the nucleus the repressor activity of Erf is lost and Erf is exported to the cytoplasm, revealing 
the DNA-promoter region of ets-2, c-myc and possibly c-fos as well as other proliferation 
inducing genes.76, 77, 102-104 Enhanced transcription of c-myc and c-fos has been proposed to 
induce proliferation, migration and dedifferentiation of VSMCs.86, 104, 105 In the present study, 
phosphorylation of Erf may also be associated with a decrease in Erf activity, accompanied by 
a higher rate of ets-2, c-myc and c-fos transcription and thus present a potential risk factor for 
the development of atherosclerosis and even tumorigenesis.102-104  
 
4.4 The role of intracellular calcium in VSMCs 
Calcium is an important regulator of different functions and processes of vascular smooth 
muscle cells.58, 59, 146 Inside the cell, calcium is stored in caveolae along the plasma membrane 
as well as in the sarcoplasmatic reticulum.1, 13, 58, 59, 65, 66 The binding of extracellular signals 
like adrenalin, angiotensin II, PDGF or LDL to membrane receptors followed by the 
activation of phospholipase C (PLC) and the formation of inositol-1,4,5-triphosphate (IP3) 
trigger the release of calcium from the sarcoplasmatic reticulum into the cytoplasm through 
IP3-receptor channels.1, 58, 59, 62, 65, 66 Additionally, depolarization of the VSMC membrane 
activates the L-type high voltage-gated Ca2+-channels located in the cell membrane, resulting 
in Ca2+ influx from the extracellular space.58, 59, 65 Increasing intracellular calcium 
concentration ultimately activates calcium-dependent ryanodin receptor channels in the 
membrane of the sarcoplasmatic reticulum, causing further increase of intracellular calcium 
concentration.58, 59  
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The rise in intracellular calcium concentration causes VSMC contraction via calcium-
calmodulin-dependent activation of the MLCK.1, 8, 13, 16, 17, 58, 59, 65 Furthermore, calcium itself 
or the change in intracellular calcium concentration acts as a second messenger and induces 
Erk-1/2 activation in VSMCs.68 Calcium is also known to regulate VSMC proliferation by 
activating the β-catenin/T-cell factor (TCF) signaling pathway via calcium-calmodulin-
stimulated phosphodiesterase 1 (PDE1).147 Blocking the rise of intracellular calcium 
concentration leads to down regulation of the lectin-like oxidized low density lipoprotein 
receptor-1 (LOX-1) and the LOX-1 pathway activity, causing inhibition of VSMC 
apoptosis.148  
In this study, depletion of intracellular calcium in VSMCs using 20 µM BAPTA/AM, alone 
or in combination with PDGF, activates Erk-1/2 phosphorylation and causes a subsequent 
increase in the phosphorylation of Erf. This is suggestive of the fact that Erk-1/2-mediated Erf 
phosphorylation is not only dependent on mitogenic stimulation but also on levels of 
intracellular calcium. 
Kip et al., showed that a reduction of intracellular calcium concentration by 30% via chelation 
(20 μM BAPTA/AM) or antagonisation (20 μM Verapamil) of calcium increases Erk-1/2 
phosphorylation and VSMC proliferation.68 These findings are in line with our results. Using 
Ca2+-channel deficient mice, they also demonstrated that animals develop vascular injuries 
based on medial wall thickening as a result of constantly reduced intracellular calcium 
concentrations.68 
In contrast to our findings and the findings of Kip et al., Yang et al., showed that a 
concentration of 30 µM BAPTA/AM leads to a significant inhibition of oxLDL-induced Erk-
1/2 phosphorylation in VSMCs.24 Apart from that, they even postulated a mitogenic effect of 
calcium by examining VSMC proliferation.24, 146 
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These differences in findings concerning the pro- or anti-proliferative effect mediated by 
levels of intracellular calcium concentration may be due to 1) the method of reducing 
intracellular calcium concentration or 2) the cell systems used in experiments.  
The present experiments additionally investigated the effect of a combination of mitogenic 
stimulus and calcium depletion on the A-10 VSMCs. The results showed that a cumulative 
impact on the cells caused a stronger phosphorylation of Erk-1/2 than each individual 
stimulus alone. These findings suggest that intracellular calcium levels mask the activation of 
MAPK pathway induced by mitogenic stimuli. However, the combination of PDGF and 
BAPTA/AM did not have the same strong effect on Erf phosphorylation as on Erk-1/2 
phosphorylation. In VSMCs treated with PDGF and BAPTA/AM, phosphorylation of Erk-1/2 
was significantly greater than in VSMCs stimulated with PDGF only (4.1-fold increase). In 
contrast, treatment with PDGF and BAPTA/AM resulted in a non-significant 1.17-fold 
increase in Erf phosphorylation compared to VSMCs stimulated with PDGF only. These 
findings indicate that not all of the information in Erk-1/2 is transmitted to Erf, thus 
supporting the notion that Erk-1/2 function as a further relay point to other downstream 
effector molecules.  
The current results imply that, in combination with mitogens, the decrease of intracellular 
calcium concentration regulates Erf phosphorylation and represents a potential proliferative 
stimulus which may lead to alterations in vascular smooth muscle cell functions.37-39  
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4.5  Limits of the study  
• In the present study, rat embryonic thoracic aorta smooth muscle cells (A-10) were 
used. It would be worth performing the experiments with other smooth muscle cell 
lines and also with primary vascular smooth muscle cells from mouse and rat.  
• The role of Erf and its regulation by Erk-1/2 and calcium was not examined in intact 
arteries. 
• Throughout the study only PDGF and LDL were used as stimulants. The effect of 
other agonists such as mitogens, inflammatory cytokines or reactive oxygen species on 
Erf activation was not investigated.  
• Besides Erk-1/2 and calcium, other possible regulators of Erf phosphorylation were 
not studied. Furthermore, the localisation and nuclear shuttling of Erf in VSMCs was 
not analyzed.  
• BAPTA/AM was used as a chelator of intracellular calcium. However, the level of 
intracellular calcium before and after BAPTA/AM application was not measured. 
Moreover, the role of other calcium chelators was not examined for the purposes of 
this study. Finally, the effect of BAPTA/AM on intact arteries was not taken into 
consideration. 
• A further insight into the function of Erf in VSMCs could be achieved by the silencing 
of Erf expression at the gene level. This could provide knowledge about the role of Erf 
in cell proliferation, migration and differentiation. 
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4.6  Conclusions and clinical implications 
Atherosclerosis and its sequelae coronary heart disease (CHD)/coronary artery disease (CAD) 
is the leading single most common cause of death in almost all of the Western industrialized 
countries (in Canada the leading cause of death in 2007 were malignant neoplasms).149-152 In 
the United States in 2006, the prevalence of CHD was 9.1% in men and 7.0% in women. 
Accordingly, the prevalence for the total population (both sexes) was 7.9%. The death rate 
attributed to CHD in 2006 was 135/100’000.150 In Europe 21% of the adult male and 22% of 
the adult female population died of CHD in 2008. However, death rates due to CHD are 
higher in Eastern and Central Europe than in Northern, Western and Southern Europe. In 
Switzerland for instance, the age-standardized death rate for CHD in 2004 was 20/100’000.152  
According to a Swiss study by Faletra et al., coronary artery plaques (CAP) can be found in 
49.9% of completely asymptomatic patients, whereby 18% of the patients have no 
cardiovascular risk factors whatsoever.153 In the United States, the prevalence of coronary 
artery calcification is 17.6% in white men and 11.3% in white women in the 33-45 year-old 
age group and 70.4% in white men and 44.6% in white women in the 45-84 year-old age 
group.154, 155 The data for developing countries such as India suggest a prevalence of 3-9% for 
coronary atherosclerosis in the general population.151  
However, the mortality rate due to CHD and myocardial infarction (MI) has been declining. A 
community study in the United States showed a drop in the annual death rate due to CHD of 
1.6% - 4.4%.156 The overall reduction in CHD mortality for the United States from 1996 – 
2006 amounted to 35.9%.150 The first decline in CHD mortality in the United States was 
observed in 1975.157 In Switzerland, the age-standardized death rates for CHD dropped from 
60/100’000 in 1972 to 20/100’000 in 2005.152 
Despite the decline in CHD and MI mortality, the risk factors, including arterial hypertension, 
nicotine abuse, diabetes, hypercholesterolemia, obesity and lack of sufficient physical 
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exercise are widely spread and reaching pandemic proportions - so far, prevention has been 
the only effective therapy.  
Exploring the mechanisms of atherogenesis is a major field in medical science because it 
affects the survival of an increasingly aging population, particularly in Western countries. 
However, another reason for the great interest in this field is that pharmaceutical companies 
are willing to spend considerable amounts on scientific findings that will enable them to 
develop drugs that will allow the Western civilization to maintain its unhealthy and decadent 
lifestyle. 
Although a major part of the molecular processes in VSMCs during atherogenesis is still not 
completely understood, research in this field has shown that VSMCs play a central role. 
Furthermore, data indicate that the MAPK pathway is critical to VSMCs in the development 
and progression of atherosclerosis. 
In the last few years the MAPK pathway has gradually become the center of attention in 
cancer research.37-41, 158, 159 Biochemical mutation and activation analysis have provided 
evidence that in a variety of types of cancer, the MAPK pathway, and especially the Ras-Raf-
Mek-Erk-1/2 pathway, is constitutively overactivated.158, 159 The underlying mechanisms 
leading to this condition are manifold, although the most common is the mutation of a 
member of the MAPK pathway. In colorectal cancer, for example, mutational analysis studies 
were able to identify b-Raf (V600E) mutations in 15.6% and k-Ras mutations in 22% of the 
cases.160  The presence of b-Raf mutations is associated with a poor prognosis of survival and 
a higher tumor grade, whereas mutations of the k-Ras gene have no impact on overall survival 
or progression-free survival but provide additional information for appropriate treatment with 
tyrosine kinase receptor inhibitors (TKIs).161-167 Thus, the mutational statuses of k-Ras and b-
Raf represent prognostic and predictive factors of colorectal cancer.165 Mutation of k-Ras in 
non-small cell lung cancer (NSCLC) in contrast is a predictor of a poorer clinical outcome.168  
 - 49 - 
Not only mutations of the MAPK pathway can induce its overactivation; mutations upstream 
of the cascade mediate the same effect.158, 169, 170 For example mutations of epidermal growth 
factor receptor (EGFR), a tyrosine kinase receptor, occur in approximately 13% of non-small 
cell lung cancers (NSCLC) and are associated with a survival benefit and better response to 
tyrosine kinase receptor inhibitors (TKI) as well as to chemotherapy.168, 171 However, when an 
EGFR mutation occurs simultaneously with a k-Ras mutation, the response to TKIs is much 
weaker.168, 171  
The formation of fusion genes through translocation of chromosomal regions can also lead to 
overactivation of the MAPK pathway.71 The best known translocation is probably the t(9;22) 
translocation, resulting in Philadelphia chromosome 22.158, 172 Its gene product is the fusion-
protein Bcr-Abl, a constitutively activated tyrosine kinase that causes increased activation of 
the MAPK pathway by permanent phosphorylation of Ras and Raf.173-175 The t(9;22) 
translocation is found in almost all cases of chronic myeloid leukemia (CML), however, 
according to recent studies, it is probably not the only translocation and translocation is not 
the only reason for malignant transformation of the hematopoietic cells.158, 172, 176, 177 
Growing insight into the role of the MAPK pathway in different types of solid and 
hematopoietic cancers has led to the development of targeted agents, constructed to attack the 
specific properties of tumor cells. Screening for designated mutations depending on the origin 
of the malignant tissue provides the necessary information for individualized therapy.167 One 
of the most widely applied classes of targeted cancer therapeutics are the so called small-
molecule tyrosine kinase inhibitors (TKIs), monoclonal antibodies against activated tyrosine 
kinases of different cancer types.167, 168, 172, 178-183 The best known examples are the Bcr-Abl 
kinase inhibitor Imatinib (Glivec®), used in the treatment of Philadelphia-positive CML,184 
epidermal growth factor receptor (EGFR) inhibitor Trastuzumab (Herceptin®), used in the 
treatment of  human epidermal growth factor receptor-2/neu (Her-2/neu)-positive breast 
cancer 183 and the EGFR inhibitor Erlotinib (Tarceva®), used in the case of EGFR-mutation 
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positive NSCLC.180 However, inhibitors of Ras, b-Raf and Mek-1/2 are also currently being 
tested as cancer therapeutics.179 
The fact that the MAPK pathway is ubiquitously expressed and plays a key role in a variety of 
intracellular processes, as well as in the development of human cancer, implies that it could 
also be involved in the development of other diseases.  
Thus, as a next step, our knowledge of the MAPK pathway and receptor tyrosine kinase 
mutations, as well as fusion-protein formation activating the MAPK pathway during 
tumorigenesis, should be adapted to the model of atherogenesis. VSMC proliferation, 
dedifferentiation and migration during intimal hyperplasia formation are the response to a 
mitogenic stimulus. Up until now it has been assumed that these events are triggered by an 
external signal. However, considering the most recent discoveries in cancer research, an 
endogenous, mutational origin of these changes is conceivable, especially in patients prone to 
atherosclerosis. Future studies should focus on answering the question whether mutations or 
translocations might possibly be the cause of atherosclerosis. 
The drugs currently available on the market for the therapy of atherosclerosis and CHD/CAD 
focus on fighting the risk factors of atherosclerosis such as hypercholesterinemia (lipid-
lowering agents, statins) and hypertension (ACE-inhibitors, beta-blockers), or on preventing 
acute thrombus formation (thrombocyte aggregation inhibitor, Aspirin). None of these agents 
are targeted to attack the essential processes of atherogenesis. Thus, taking the fact into 
consideration that the MAPK pathway is critical in the regulation of VSMCs during 
atherogenesis, it would be worth investigating the effects of TKIs on the development and 
progression of atherosclerosis.  
Several members of the Ets-domain transcription factor family are also activated excessively 
in the course of mutational overactivation of the MAPK pathway. However, the Ets-domain 
transcription factors can also directly acquire constitutive activity through gene mutation or 
chromosome translocation with protein fusion. The resulting deregulation of the Ets-domain 
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transcription factors then leads to uncontrolled proliferation of the lesional cell and finally 
development of solid cancer and leukemia. 70-72, 74-76, 85, 87-89, 185-188  
In breast cancer, Ets-1 is overexpressed and is consequently involved in the progression of the 
disease and metastasis. The invasive behaviour of this type of cancer, however, is not only 
mediated by the overexpression of Ets-1 in the tumor cells, but also by overexpression in the 
endothelial cells and VSMCs of the blood vessel supply.70, 71, 75, 87-89 Thus, Ets-1 has become a 
prognostic marker for poor survival prospects in connection with breast cancer.87, 89  
The transcription factor Ets-2 is also associated with certain types of human cancers. Hsu et 
al., were able to show that in two of the most common types of solid malignomas, breast and 
prostate cancer, there is a crucial rise in Ets-2 expression.76 In the course of malignant 
transformation, activated Ets-2 increases the level of human telomerase reverse transcriptase 
(hTERT) expression, thereby decreasing the apoptosis rate of cells with damaged DNA.26, 188  
However, Ets-1 and Ets-2 do not only play a crucial role in tumorigenesis and cancer 
progression; they are also essential for normal development of the mouse and chicken 
embryonic vascular system.26, 75, 76, 83, 91 Also, Ets-1 is known to be involved in human 
angiogenesis as well as tumor vascularisation, vascular inflammation, rupture of cerebral 
aneurysms, and finally, atherogenesis.26, 70-73, 75, 80, 82, 85-89, 98 
In analogy to the MAPK pathway the knowledge of Ets-1 and Ets-2 mutations in human 
cancer could be applied to the model of atherosclerosis. Possible mutation/s-associated 
overactivation of Ets-1 and Ets-2 during atherogenesis could be a potential field to 
investigate. Various groups have been able to show participation of Erf in the 
pathomechanisms of disease development in different cell systems as well as in the 
carcinogenesis of various cancer types due to a downregulation of Erf transcription and 
repressor activity.122, 123, 125  
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In lung cancer, the microRNA miR-7, whose expression is induced by an activating mutation 
of epidermal growth factor receptor (EGFR) and subsequent upregulation of the Ras/Erk 
pathway, decreases the level of Erf by direct targeting. As a consequence, growth and 
proliferation of the lesional cell is increased, finally causing tumorigenesis.122 Hester el al., 
provide evidence that Erf negatively regulates the cell cycle genes c-myc and cdc2, and 
thereby affects cell cycle progression and proliferation. Moreover, they demonstrate that 
constitutive activation of the MAPK pathway by v-Abelson leukemia virus-transformed 
mouse leukemic monocytic cells causes constitutive inactivation of Erf repressor activity, 
suggesting that Erf is a specific target for inactivation by oncogenes in the process of 
malignant transformation.123 
On the other hand, overexpression of Erf can also be the cause of disease development. In 
Duchenne muscular dystrophy (DMD) it represses the expression of utrophin, a homologue of 
the defectively or non-expressed dystrophin gene, and potentially contributes to disease 
deterioration.126  
Prior to this study little was known about the expression of Erf in VSMCs and still nothing is 
known about the target genes of Erf and how Erf regulates transcriptional repression in 
VSMCs, with the help of co-factors. Although an enhanced Erf phosphorylation is known to 
cause ets-2 and c-myc deregulation in mouse embryonic fibroblasts and thus lead to increased 
tumorigenesis,102, 104 the question remains as to under which conditions in VSMCs Erf is over-
phosphorylated and thus looses its protective function, thereby allowing enhanced ets-2 and c-
myc transcription. The answer to that question could be of major relevance in atherosclerosis 
research.  
The present study shows that Erf is phosphorylated extensively via the Mek/Erk-1/2 MAPK 
pathway in VSMCs following mitogenic stimulation. This novel finding could help us 
understand the development of the various diseases of the vessel wall including 
atherosclerosis, and thus help in the development of preventative or therapeutic agents. For 
 - 53 - 
example, the targeted activation of Erf transcription or inhibition of Erf phosphorylation could 
lead to the prevention or attenuation of VSMC proliferation, dedifferentiation and migration 
to the intima during intimal thickening. In this way atherosclerosis and its far-reaching 
consequences could be treated effectively or even prevented from developing. In addition, 
quantitative measurements of phosphorylated Erf in VSMCs, perhaps within a puncture of the 
arteria radialis, could contribute to the development of a risk-stratification score for 
atherosclerosis. 
Based on the results emerging from this work an investigation of the effect of an aimed 
increase in [Ca2+]i in VSMCs on proliferation, migration and apoptosis or even on the 
development and progression of atherosclerosis could represent the next step towards the 
development of therapeutic or preventative drugs. Furthermore, due to our findings in relation 
to calcium concentrations, studies suggesting the use of calcium channel blockers (CCB) as a 
potential additive in the treatment of atherosclerosis and other vascular diseases should be 
reconsidered.189, 190  
In the last few years a new type of targeted therapy involving micro-RNAs (miRNAs) against 
vascular disease and phenotypic switching of VSMCs has been increasingly gaining in 
importance. These ubiquitously-expressed specific non-coding ribonucleic acids regulate 
translation of their particular target RNA post-transcriptionally.191-195 Special attention has 
been given to the miRNA miR-145, which is physiologically expressed at a high level in 
VSMCs of healthy arterial walls and positively regulates the expression of VSMC markers 
such as SM α-actin and MHC.191, 195 Zhang et al., showed that the expression of miR-145 is 
downregulated significantly in VSMCs of balloon-injured arteries with neointimal 
hyperplasia and dedifferentiated VSMCs.191, 195  
In the future miR-145, as well as other micro-RNAs, could become the novel markers of 
VSMC phenotypic switching and starting point for therapeutic approaches to vascular 
remodeling diseases.191-195 By directing the focus towards the development of Erf-enhancing-
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miRNAs, phosphorylation of Erf in mitogenically-challenged VSMCs could be compensated, 
allowing continued repression of ets-2 and c-myc transcription and blockage of cell cycle 
progression and neointimal formation.  
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